Saptalis pharm`s Generic Cyclosporine Receives Approval in U.S
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%
Teva Pharma`s Generic Cyclosporine Receives Approval in the U.S.
Enforcement Report - Week of December 13, 2023
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization
EAST HANOVER, N.J., Nov. 24, 2023 /PRNewswire/ -- Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing. The issue was identified during an investigation of crystallization in a different lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL. No other Sandimmune formulations are impacted.
Enforcement Report - Week of September 27, 2023